Nivolumab, a recombinant, humanized monoclonal antibody designed to binds to PD1—an immune checkpoint molecule, had been studied for its therapeutic effect in a couple of trials enrolling NPC patients. The gene discussed is PDCD1; the disease is nasopharyngeal carcinoma.